• 1
    Bellomo R, Cass A, Cole L et al. Intensity of continuous renal-replacement therapy in critically ill patients. N. Engl. J. Med. 2009; 361: 16271638.
  • 2
    Finfer S, Cass A, Gallagher M, Lee J, Su S, Bellomo R. The RENAL (Randomised Evaluation of Normal vs. Augmented Level of Replacement Therapy) study: statistical analysis plan. Crit. Care Resusc. 2009; 11: 5866.
  • 3
    Finfer S, Heritier S. The NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) Study: statistical analysis plan. Crit. Care Resusc. 2009; 11: 4657.
  • 4
    Myburgh J, Li Q, Heritier S, Dan A, Glass P. Statistical analysis plan for the Crystalloid Versus Hydroxyethyl Starch Trial (CHEST). Crit. Care Resusc. 2012; 14: 4452.
  • 5
    Thompson BT, Ranieri VM, Finfer S et al. Statistical analysis plan of PROWESS SHOCK study. Intensive Care Med. 2010; 36: 19721973.
  • 6
    Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann. Intern. Med. 2008; 148: 295309.
  • 7
    Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments. Ann. Intern. Med. 2008; 148: W6066.
  • 8
    Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 16441655.
  • 9
    The NICE-SUGAR investigators. Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med. 2009; 360: 12831297.
  • 10
    Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 2004; 30: 589596.
  • 11
    Peake SL, Bailey M, Bellomo R et al. Australasian resuscitation of sepsis evaluation (ARISE): a multi-centre, prospective, inception cohort study. Resuscitation 2009; 80: 811818.
  • 12
    The ARISE investigators, The ANZICS APD management committee. The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand. Crit. Care Resusc. 2007; 9: 818.
  • 13
    Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G. Long-term mortality and medical care charges in patients with severe sepsis. Crit. Care Med. 2003; 31: 23162323.
  • 14
    Angus DC, Laterre PF, Helterbrand J et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit. Care Med. 2004; 32: 21992206.
  • 15
    Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 2001; 345: 13681377.
  • 16
    Reade MC, Huang DT, Bell D et al. Variability in management of early severe sepsis. Emerg. Med. J. 2010; 27: 110115.